COMT基因多态性和抗精神分裂症药物疗效关系的Meta分析

发布时间：2018-01-11 17:05

本文关键词：COMT基因多态性和抗精神分裂症药物疗效关系的Meta分析　出处：《中南大学学报(医学版)》2015年06期 　论文类型：期刊论文

【摘要】：目的:探讨儿茶酚胺氧位甲基转移酶(catechol O-methyltransferase,COMT)Val108/158 Met基因多态性与抗精神分裂症药物疗效之间的关系,为抗精神分裂症药物的个体化用药提供一定的依据。方法:计算机检索Pub Med,Embase,Cochrane Library,中国知网,万方,维普,中国生物医学文献数据库获取相关文献。在评价原始研究质量,提取有效数据后,采用Stata12.0进行统计分析。结果:共筛选出9篇符合标准的文献,包含868例患者。Meta分析结果显示各基因型合并后的RR值、95%CI及P值,以患者的总体症状改善情况来评价药物疗效时,Met与Val比较,RR=1.18,95%CI:1.04~1.35,P=0.013;Met/Met与Val/Val比较,RR=1.40,95%CI:1.08~1.82,P=0.010。以患者的阴性症状改善情况来评价药物疗效时,Met与Val比较,RR=1.24,95%CI:1.05~1.46,P=0.013;Met/Met与Val/Val比较,RR=1.60,95%CI:1.04~2.46,P=0.031。结论:COMT Val108/158Met基因多态性与抗精神分裂症药物疗效显著相关,其中Met基因为优势基因,对抗精神分裂症药物反应较好。
[Abstract]:Objective: to study catechol O-methyltransferase. The relationship between the polymorphism of COMT)Val108/158 Met gene and the efficacy of antipsychotic drugs. Methods: Pub Medbase Cochrane Library was searched by computer. Wanfang, Weipu, China Biomedical Literature Database to obtain the relevant documents. After evaluating the quality of the original research, extraction of valid data. Results: a total of 9 articles were selected, including 868 patients. Meta-analysis showed the RR values of the combined genotypes. 95 CI and P values were compared with Val in evaluating the efficacy of the drug according to the overall symptom improvement of the patients. P0. 013; Compared with Val/Val, Met/Met is 1.4095 CI: 1.081.82. In order to evaluate the efficacy of the drug, Met was compared with Val in comparison with RRV 1.2495 CI: 1.051.46. P0. 013; Compared with Val/Val, Met/Met is 1.6095 and CI1.042.46. Conclusion the polymorphism of the Val108/158Met gene is significantly associated with the efficacy of antipsychotic drugs, among which the Met gene is the dominant gene. The drug response to schizophrenia is good.
【作者单位】：中南大学公共卫生学院卫生统计学教研室;中南大学湘雅医院临床药理研究所;中南大学湘雅三医院药物临床研究统计分析中心;
【基金】：国家“重大新药创制”科技重大专项(2012ZX09303014-001) 湖南省自然科学基金(13JJ5017)~~
【分类号】：R749.3
【正文快照】： 第一作者(First author):陈卉,Email:chenhuiljxuan@csu.edu.cn精神分裂症患者对抗精神分裂症药物的反应各异至今仍然是治疗精神分裂症的一个重大挑战。据估计,现在的抗精神分裂症药物约只对50%的患者有效[1]。药物基因组学研究[2]表明:基因多态性在个体药物效应及药物毒性差

【参考文献】